Press release
Global Antisense and RNAi Therapeutics Market To Reflect Impressive Growth Rate by 2027| Tekmira Pharmaceuticals, Benitec Biopharma, Sanofi, Ionis Pharmaceuticals, Silence Therapeutics
Global Antisense and RNAi Therapeutics Market
This report enables both sides in market (be an established firm or a relative new entrant). It helps the established firms to know about the moves which are being performed by their competitors and also helps the new entrants in educating them about the market situations and the industry trends.
This report is quite fruitful in helping to understand the market definition and all the aspects of the market including the CAGR value and key profiles.
Ask For Complimentary Sample PDF| Request At https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-antisense-and-rnai-therapeutics-market
The major players covered in the antisense and RNAi therapeutics markets are Astellas Pharma Inc, Quark, Alnylam Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Tekmira Pharmaceuticals, Benitec Biopharma, Sanofi, Ionis Pharmaceuticals, Silence Therapeutics, Cenix BioScience, Sirnaomics, CureVac AG, BioNTech SE, Arrowhead Pharmaceuticals, Inc, Arbutus Biopharma, Marina Biotech, Inc and among others.
Insights of the report
1. What are the challenges being faced by the new entrants
2. Drivers and restrains of the market
3. To inspect the market based on product, market share and size of the product share.
4. Recent industry trends and developments
5. Potential and niche segments/regions exhibiting promising growth
Global Antisense and RNAi Therapeutics Market Scope and Market Size
Antisense and RNAi therapeutics market is segmented on the basis of indication, technology, and route of administration, end-users and distribution channel.
On the basis of indication, the antisense and RNAi therapeutics market is segmented into oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases and others.
The technology segment for antisense and RNAi therapeutics market includes RNA Interference, Antisense RNA. The RNA interference segment is further categorized into small interfering RNA (siRNA) and microRNAs (miRNAs).
Route of administration segment of antisense and RNAi therapeutics market is segmented into pulmonary delivery, intravenous injections, intra-dermal, intraperitoneal, topical and others.
On the basis of end-user, the antisense and RNAi therapeutics market is segmented into hospitals, specialty clinics and others.
Antisense and RNAi therapeutics market has also been segmented based on the distribution channel into hospital pharmacy, retail pharmacy others.
Table of Content
01: Executive Summary
02: Scope of The Report
03: Market Landscape
04: Market Sizing
05: Market Segmentation by Product
06: Five Forces Analysis
07: Customer Landscape
08: Geographic Landscape
09: Decision Framework
10: Drivers and Challenges
Get Full Table Of content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-antisense-and-rnai-therapeutics-market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Corporatesales@databridgemarketresearch.com
About Data Bridge Market Research
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Antisense and RNAi Therapeutics Market To Reflect Impressive Growth Rate by 2027| Tekmira Pharmaceuticals, Benitec Biopharma, Sanofi, Ionis Pharmaceuticals, Silence Therapeutics here
News-ID: 1936075 • Views: …
More Releases from Data Bridge Market Research
Precision gearbox market grow at a CAGR of 9.1% in the forecast period of 2022 t …
Precision gearbox market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses the market to reach at an estimated value of USD 5.9 billion by 2029 and grow at a CAGR of 9.1% in the above-mentioned forecast period.
Market Overview
This precision gearbox market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market…
Neuropathic Pain Market is expected to undergo a CAGR of 9.2% during the forecas …
Data Bridge Market Research analyses that the global neuropathic pain market, which was USD 5.86 billion in 2023, is expected to reach USD 11.86 billion by 2031, and is expected to undergo a CAGR of 9.2% during the forecast period of 2024 to 2031.
Market Overview
Neuropathic pain is a type of chronic pain caused by damage or dysfunction of the nervous system. It often presents as burning, shooting, or electric shock-kind…
Radiology market registering a CAGR of 6.20% during the forecast period of 2022- …
Radiology market was valued at USD 26.6 billion in 2021 and is expected to reach USD 43.04 billion by 2029, registering a CAGR of 6.20% during the forecast period of 2022-2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Overview
Radiology (also referred as diagnostic imaging) includes multiple tests are included in the process, which…
Cervical Retractors Market Size, Share, Trends, Key Drivers, Growth and Opportun …
Global Cervical Retractors Market report focuses on several essential parameters related to the market that includes but are not limited to a competitive landscape, brief segmentation and industrial infrastructure. This marketing report offers an in-depth overview of product specification, technology, product type and production analysis considering major factors such as revenue, cost, and gross margin. Cervical Retractors market is supposed to grow during the forecast period due to growing demand…
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand.
Browse 156 Market Data Tables and 112 Figures spread through 175…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited.
Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring…
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.
Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved…
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018!
Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led…
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.
One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and…
